Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Blood (2019) 134 (Supplement_1): 1642.

https://doi.org/10.1182/blood-2019-130148

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience

Mansour Alfayez, MD, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSc, Mary B. Rios, RN, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 5447.

https://doi.org/10.1182/blood-2018-99-117075

Published: 2018

Journal Articles

Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Marina Y. Konopleva, MD PhD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Naval G. Daver, MD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Guillermo Montalban-Bravo, MD, Mary B. Rios, RN, Sherry A. Pierce, BSN, BA, Kenichi Sakurai, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 3026.

https://doi.org/10.1182/blood-2018-99-115380

Published: 2018

Journal Articles

Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI)

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Susan M. O'Brien, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, William G Wierda, MD PhD, Naval Daver, MD, Alessandra Ferrajoli, MD, Koichi Takahashi, MD, Preetesh Jain, MBBS,MDDM,PhD, Mary B. Rios, RN, Sherry Pierce, BSN, BA, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 1609.

https://doi.org/10.1182/blood.V130.Suppl_1.1609.1609

Published: 2017

Journal Articles

Expression of Core-Binding Factor (CBF) Fusion Genes in Clonal Evolution of Chronic Myeloid Leukemia (CML).

Farhad Ravandi-Kashani, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Susan O’Brien, MD, Mary B. Rios, Jorge Cortes, MD

Blood (2004) 104 (11): 4697.

https://doi.org/10.1182/blood.V104.11.4697.4697

Published: 2004

Journal Articles

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

Jorge Cortes, Patricia Ault, Charles Koller, Deborah Thomas, Alessandra Ferrajoli, William Wierda, Mary B. Rios, Laurie Letvak, Elizabeth S. Kaled, Hagop Kantarjian

Blood (2003) 101 (12): 4714–4716.

https://doi.org/10.1182/blood-2003-01-0081

Published: 2003

Journal Articles

Evidence of the existence of a factor that induces C3 receptors on bone marrow cells

M Calcagno, B Rios, A Fragoso, MA Arciga, G Cabrera, R Torres, B Weiss-Steider

Blood (1983) 61 (2): 403–407.

https://doi.org/10.1182/blood.V61.2.403.403

Published: 1983

NARROW

The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Ponatinib and Bosutinib Discontinuation in Chronic Myeloid Leukemia (CML): Single Center Experience

Dynamic Personalized Assessment in Patients with Chronic Myeloid Leukemia in Chronic Phase

Incidence of Secondary Malignancies in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the Era of Tyrosine Kinase Inhibitors (TKI)

Expression of Core-Binding Factor (CBF) Fusion Genes in Clonal Evolution of Chronic Myeloid Leukemia (CML).

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

Evidence of the existence of a factor that induces C3 receptors on bone marrow cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only